Please login to the form below

Not currently logged in
Email:
Password:

BioCryst Appoints new senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals hires Dr Elliott T Berger as senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals has hired Dr Elliott T Berger as senior vice-president of regulatory affairs.

Dr Berger brings to BioCryst a long and successful track record in obtaining approval from the FDA for numerous drugs. He will play an integral role in BioCryst's planned clinical research programmes for treatments for influenza, leukaemia and lymphoma, autoimmune diseases and transplant rejection, and will work in close collaboration with health authorities in the US and other countries.

Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Most recently he was vice-president of regulatory affairs and quality assurance and head of global regulatory strategy at EMD Pharmaceuticals, the North American subsidiary of Germany-headquartered Merck KGaA.

Berger held a variety of research positions at Merck Research Laboratories in West Point, Pennsylvania, most recently as Senior Director, Regulatory Liaison. He has submitted and managed over 10 New Drug Applications and numerous Investigational Drug Applications in the areas of oncology, diabetes, cardiovascular disease, and neurology.

8th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics